A mammalian, glutaminase-free asparaginase enhances venetoclax activity in preclinical AML models with chromosome 7 deletion

IntroductionAcute myeloid leukemia (AML) remains a malignancy with poor prognosis andfrequent resistance to standard therapies, underscoring the urgent need for novel treatmentstrategies. In this preclinical study, we evaluated the anti-leukemic efficacy of EBD-300, a novelmammalian-derived asparagi...

Descrición completa

Detalles Bibliográficos

Principais autores:	Dhabya Majid, Zhe Wang, Amanda M. Schalk, Bin Yuan, Qi Zhang Tatarata, Jessica L. Root, Araceli Isabella Garza, Mhd Yousuf Yassouf, Basant T. Gamal, Sammy Feri-Borgogno, Annie Hoai Nguyen, Marina Konopleva, Evelien Peeters, Ying Su, Patrick K Reville, Farhad Ravandi-Kashani, Arnon Lavie, Hussein A. Abbas
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2026-02-01
Series:	Frontiers in Oncology
Assuntos:	acute myeliod leukemia AML AML with deletion 7 combination treatment leukemia venetoclax
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1606239/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!